Abstract
In this issue of Blood, Pettirossi et al, including Drs Tiacci and Falini, who led the effort in 2011 defining the BRAF-V600E driving mutation in hairy cell leukemia (HCL),provide extensive laboratory studies showing that inhibitors of BRAF-V600E and/or mitogen-activated protein kinase kinase (MEK) reach their targets and cause HCL cell death
MeSH terms
-
Antineoplastic Agents*
-
Humans
-
Imidazoles*
-
Indoles*
-
Leukemia, Hairy Cell / drug therapy*
-
Leukemia, Hairy Cell / genetics*
-
Oximes*
-
Pyridones*
-
Pyrimidinones*
-
Sulfonamides*
-
Transcriptome / drug effects*
-
Vemurafenib
Substances
-
Antineoplastic Agents
-
Imidazoles
-
Indoles
-
Oximes
-
Pyridones
-
Pyrimidinones
-
Sulfonamides
-
Vemurafenib
-
trametinib
-
dabrafenib